Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMEC-SHORT & GAMEC-ANTHRACYCLINE for relapsed germ cell tumours
2006-001963-52Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin in germ cell tumor (GCT) (2 arms), sponsored by Queen Mary University of London. Primary endpoints: progression free survival and response rate. Started May 2006; status: terminated.
02
Drugs
cisplatin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2006-001963-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001963-52.